ADBIOTECH to Acquire 12.28% Stake in Onheal for 9.97 Billion KRW in Cash – Related-Party Transaction and Business Diversification
ADBIOTECH decided to acquire 181,269 shares of Onheal for 9.97 billion KRW in cash, a transaction representing 20.6% of total assets and 29.25% of equity.
Onheal operates in pet healthcare and non-clinical CRO; the transaction qualifies as a related-party deal because ADBIOTECH's CEO also serves as Onheal's co-CEO.
Onheal has reported consecutive net losses for three years, including a net loss of 2.12 billion KRW in 2025, and faces near-negative equity. The acquisition is funded with existing cash, so no share dilution occurs.
[AI Summary]ADBIOTECH is acquiring a stake in a related party Onheal for 9.97 billion KRW cash. Onheal's weak financials and planned large CAPEX suggest limited near-term profitability improvement. While no equity dilution exists, the significant cash outflow and potential conflict of interest warrant investor caution.
KOSDAQ Filing Information
Report on Major Matters (Decision to Acquire Stocks and Investment Securities of Other Corporation)